牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-20-001786 Act: 34 Size: 106 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-004069 Act: 34 Size: 28 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-20-038585 Act: 34 Size: 119 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-003604 Act: 34 Size: 829 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-003461 Act: 34 Size: 31 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-003406 Act: 34 Size: 547 KB 网页链接
$灿菲特生物制药(CANF)$ 424B4 Prospectus [Rule 424(b)(4)] Accession Number: 0001213900-20-003343 Act: 33 Size: 3 MB 网页链接
$灿菲特生物制药(CANF)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001213900-20-003187 Act: 34 Size: 60 KB 网页链接
$灿菲特生物制药(CANF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-20-000305 Act: 33 Size: 1 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-003086 Act: 34 Size: 25 KB 网页链接